Univercells S.A. has acquired SynHelix, which aims to debottleneck biotherapeutics expansion by providing a scalable, robust, and automated DNA synthesis technology that develops extended DNA fragments additionally, with improved purity, in a single step in a cGMP-compliant setup.SynHelix’s offering will complement Quantoom Biosciences SA’s (Quantoom) RNA platform, which is creating an end-to-end RNA synthesis technology.
Until recently, AdBio Partners, a French life sciences venture finance business, has backed SynHelix. After the sale, SynHelix will be renamed Quantoom Research Center, a distinct legal organization and new Univercells Group subsidiary based in France. Both SynHelix and AdBio’s founders would eventually become minority shareholders in Univercells.
SynHelix intends to integrate this technology into Quantoom’s automated platform, which will include a “new generation DNA bioreactor” that will bring record productivity and cost savings for both R&D and manufacturing demands.SynHelix is a member of Genopole, France’s top biocluster and incubator for exceptional biotechnology initiatives, which provides a unique environment for academics and businesses looking to develop and progress their research.